Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Oric Pharmaceuticals, retaining the price target of $17.00.

Yigal Nochomovitz has given his Buy rating due to a combination of factors tied to both risk and opportunity around ORIC’s epigenetic pipeline. He distinguishes rinzimetostat’s EED-targeting mechanism and prostate cancer focus from tazemetostat’s EZH2 inhibition in indolent lymphoma, arguing that disease biology and intended use point to lower cumulative exposure and a more favorable long‑term safety profile.

He further notes that prior EZH2 experience, including prolonged Phase 2 treatment durations and potential stem cell disruption in lymphoma, may not be directly applicable to rinzimetostat’s shorter expected courses in an older prostate cancer population. While he stresses that PRC2 inhibitors require standard hematologic monitoring, he views the safety concerns as manageable and appropriately contextualized, which supports a constructive outlook and underpins his Buy / High Risk stance alongside a projected 24% upside in the shares.

Nochomovitz covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Zenas BioPharma, Inc., and Zai Lab. According to TipRanks, Nochomovitz has an average return of 3.0% and a 39.35% success rate on recommended stocks.